Jonathan Sheena Sells 2,700 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Jonathan Sheena sold 2,700 shares of the business’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $127.57, for a total transaction of $344,439.00. Following the completion of the sale, the insider now owns 284,741 shares in the company, valued at $36,324,409.37. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Jonathan Sheena also recently made the following trade(s):

• On Thursday, August 15th, Jonathan Sheena sold 12,000 shares of Natera stock. The shares were sold at an average price of $121.01, for a total transaction of $1,452,120.00.
• On Monday, August 12th, Jonathan Sheena sold 2,700 shares of Natera stock. The shares were sold at an average price of $113.82, for a total transaction of $307,314.00.
• On Monday, July 1st, Jonathan Sheena sold 2,700 shares of Natera stock. The stock was sold at an average price of $108.87, for a total value of $293,949.00.

Natera Trading Up 0.5 %

NASDAQ NTRA opened at $127.78 on Friday. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $132.01. The company has a market capitalization of $15.69 billion, a price-to-earnings ratio of -40.96 and a beta of 1.53. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The firm’s fifty day moving average price is $114.45 and its 200 day moving average price is $105.43.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The business had revenue of $413.35 million for the quarter, compared to analysts’ expectations of $343.00 million. During the same quarter in the previous year, the firm earned ($0.97) earnings per share. The business’s revenue was up 58.1% compared to the same quarter last year. On average, sell-side analysts expect that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NTRA has been the topic of several research reports. Jefferies Financial Group began coverage on shares of Natera in a research report on Monday, June 3rd. They set a “buy” rating and a $142.00 price target on the stock. Piper Sandler reissued an “overweight” rating and issued a $150.00 price target on shares of Natera in a research report on Friday, September 13th. TD Cowen increased their price objective on Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Robert W. Baird lifted their price objective on Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Finally, StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research note on Wednesday, August 28th. One research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and a consensus price target of $120.07.

Institutional Investors Weigh In On Natera

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Itau Unibanco Holding S.A. purchased a new position in shares of Natera during the second quarter worth approximately $28,000. Quarry LP grew its position in Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares during the last quarter. GAMMA Investing LLC increased its stake in Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 108 shares during the period. YHB Investment Advisors Inc. purchased a new stake in shares of Natera in the first quarter valued at about $36,000. Finally, Principal Securities Inc. acquired a new stake in shares of Natera during the fourth quarter worth about $32,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.